Nakashima K, Okada K, Iwao Y, Tada I, Suzuki K, Aramaki M, Kim Y I, Kobayashi M, Mori K, Takeyama M
First Dept. of Surgery, Medical College of Oita.
Gan To Kagaku Ryoho. 1991 Aug;18(11):1764-8.
The efficacy of combination therapy of anticancer agent-Lipiodol Emulsion for hepatic arterial infusion and regional hyperthermia was studied in 102 patients with nonresectable hepatoma. 5-FU, MFA, CDDP and MFA-CDDP were used as anticancer agents in 13, 44, 26 and 19 patients, respectively. One year survival rates of the each group were 9% (1/13, 5-FU-treated), 29% (12/44, MFA-treated), 43% (11/26, CDDP-treated) and 55% (10/19, MFA-CDDP-treated). Tumor regression was found in one out of 11 (9.1%), 11 out 41 (26.8%), 6 out of 23 (26.1) and 9 out of 19 patients (47.4%), respectively. The regional hyperthermia was particularly efficacious for patients with advanced hepatoma (E3 and E4) and clinical stage II, III; 5 out of 32 patients (16%) receiving arterial infusion and hyperthermia survived more than 1 year while all 15 patients without hyperthermia died within 11 months (p less than 0.01). Our data indicate that repeated arterial infusion of MFA and CDDP Lipiodol Emulsion was most effective for nonresectable liver cell cancer, and the regional hyperthermia prolonged the survival of patients who had advanced hepatoma with poor liver function.
对102例无法切除的肝癌患者研究了抗癌剂-碘油乳剂肝动脉灌注联合区域热疗的疗效。分别有13例、44例、26例和19例患者使用5-氟尿嘧啶（5-FU）、丝裂霉素（MFA）、顺铂（CDDP）和MFA-CDDP作为抗癌剂。每组的1年生存率分别为9%（1/13，5-FU治疗组）、29%（12/44，MFA治疗组）、43%（11/26，CDDP治疗组）和55%（10/19，MFA-CDDP治疗组）。肿瘤缩小分别见于11例中的1例（9.1%）、41例中的11例（26.8%）、23例中的6例（26.1%）和19例中的9例（47.4%）。区域热疗对晚期肝癌（E3和E4）及临床分期II、III期患者特别有效；32例接受动脉灌注和热疗的患者中有5例（16%）存活超过1年，而15例未接受热疗的患者均在11个月内死亡（P<0.01）。我们的数据表明，重复动脉灌注MFA和CDDP碘油乳剂对无法切除的肝细胞癌最有效，区域热疗延长了肝功能差的晚期肝癌患者的生存期。
